OTCQX:MRVFF - Post by User
Post by
ValueCapon Feb 25, 2020 8:01am
248 Views
Post# 30729646
Great quarter and year end
Great quarter and year end 8.6 million quarterly ebitda vs estimate 7.8. Annual ebitda 28.1 million vs 26.1 estimate
Great Blexten and Cambia growth.
Swiss approval of Pennsaid 2% and launch this year.
Anticipated Suvexx approval this year and launch in 3Q